All In Biotech

NDA 009637 · Epic Pharma LLC

Hydrocortisone Acetate

Hydrocortisone Acetate · Injection

Discontinued

Last checked: Nov 20, 2026Latest source record: Jun 25, 1997 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Jun 25, 1997

Approved uses

1

Original approval plus efficacy supplements

Registered trials

754

149 Phase 3, 82 recruiting

FAERS reports

5,445

4,776 serious, 1,614 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 25, 1997 Original approval · Type 5 - New Formulation or New Manufacturer
2 products under this application
  • HYDROCORTISONE ACETATE · HYDROCORTISONE ACETATE 25MG/ML · INJECTABLE, INJECTION · Discontinued
  • HYDROCORTISONE ACETATE · HYDROCORTISONE ACETATE 50MG/ML · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Hydrocortisone" as an intervention, any sponsor and status, largest first.

All 754 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective2,145
  • fatigue2,011
  • pain1,988
  • abdominal discomfort1,985
  • systemic lupus erythematosus1,952
  • rash1,933
  • alopecia1,914
  • rheumatoid arthritis1,845
  • swelling1,835
  • glossodynia1,823
  • pemphigus1,822
  • hepatic enzyme increased1,790

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20047
200515
200654
200715
200811
200918
201019
201120
201248
201329
201451
201571
201694
201791
2018147
2019218
2020315
2021749
2022898
2023760
2024855
2025642
2026318

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Hydrocortisone Acetate (Hydrocortisone Acetate)

2024 spending

$937

Beneficiaries

13

20 claims

Per beneficiary

$72

$2.07 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$890
2024$937

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,630 on PubMed

Sponsor: Epic Pharma LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.